This white paper highlights the capabilities of a true end-to-end service, which can be used to generate whole-tissue data for enhanced histological context and a truly unbiased, reproducible approach to spatial analysis in oncology clinical trials.

Explore the impact of biomarker testing in metastatic NSCLC. This whitepaper demonstrates how guideline-based testing and targeted therapies significantly improve survival, offering actionable insights to enhance outcomes and address disparities in care.